The Swift Biosciences team combines excellence in science with superior business skills to deliver first-in-class library preparation for next-generation sequencing. The considerable experience, expertise, and commitment of our exceptional leaders and colleagues enable us to extend our impact and achieve success.
Timothy Harkins, PhD
President & CEO
Tim has served as President & CEO of Swift Biosciences since August 2015. He has 20 years of genomics experience, holding both R&D and commercial positions, as well as 60+ peer-reviewed publications that include more than 50 in the next-generation sequencing market. Prior to Swift Biosciences, Tim was responsible for new market development for Life Technologies on both their SOLiD™ and Ion Torrent™ next-generation sequencing platforms. As previous Director of Marketing at Roche, he was responsible for developing the market for the first next-generation sequencing platforms: 454 Life Sciences’ GS20 and GS FLX, Titanium, and Junior. During his free time, Tim is an avid skier and can often be found on the slopes at Grand Targhee, WY.
Chief Commercial Officer
Haley joined Swift in January 2016. He has 25+ years of industry experience steering commercial teams at market-leading companies, and has developed reagent businesses in both Sanger sequencing and next-generation sequencing markets. For the past five years, Haley has managed marketing and sequencing application-specific sales teams for Illumina, helping to drive growth rates greater than 25% with sales over $1B/year. He has held business roles at Applied Biosystems, Molecular Dynamics, Amersham-Pharmacia Biotech, and PerkinElmer. Haley is a retired semi-pro big wave surfer and can often be found in the waves near his home in Pacifica, CA.
Vladimir Makarov, PhD
Chief Scientific Officer
Vladimir co-founded Swift Biosciences in 2010 with a strong track record of developing novel research and diagnostic methods and tools. His experience spans more than 30 years in cutting edge molecular biology and life science research, with broad expertise in different fields of science including physics, molecular biology, genomics, and molecular diagnostics. Vladimir has authored more than 30 issued and pending patents and 60 scientific publications. He has co-founded two biotech start-ups, leading to development and commercialization of more than 10 different products in the research tools and diagnostics space. Vladimir received his PhD in Physics and Mathematics from St. Petersburg University (Russia) and has held senior scientist positions at both the University of Michigan (Ann Arbor) and the Institute of Molecular Biology (Moscow).
Vice President, Global Marketing
Candia joined Swift in January 2017 and brings over 25 years of biotechnology experience, including product development, product management, and market development, to the Swift Management Team. Prior to joining Swift, Candia served as Director of Single-cell Genomics at Fluidigm Corporation, a microfluidics and mass cytometry technology manufacturer, where she was responsible for market research, strategic planning, life cycle management, and market development. She also previously directed the strategic marketing for DNA applications within Affymetrix, Inc., including cytogenetics and genotyping product lines, and held various positions during her tenure at Applied Biosystems, including product development, customer support, and product marketing for DNA sequencing and PCR-based applications. Candia earned a Bachelor’s degree in Integrative Human Biology from the University of California, Berkeley.
Vice President, Finance
Eric joined Swift in April 2013 after serving as a consultant to the company for two years. He has 15+ years of early stage operations experience, including over 10 years in the life science industry. Prior to joining Swift, Eric was Director of Finance at Atterocor where he was responsible for establishing the financial operations of the company from inception through seed and Series A ($16M) fund raising. Prior to Atterocor, Eric was Managing Director of Diag Ventures, a consultancy focused on financial and operational development of early stage companies. He earned an MBA with a concentration in Finance and Corporate Strategy from the University of Michigan’s Ross School of Business, a BA from the University of Michigan, and is a licensed CPA in the state of California.